232 related articles for article (PubMed ID: 37030280)
1. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Pignata S; Oza A; Hall G; Pardo B; Madry R; Cibula D; Klat J; Montes A; Glasspool R; Colombo N; Pete I; Herrero Ibáñez A; Marín MR; Ilieva R; Timcheva C; Di Maio M; Blakeley C; Taylor R; Barnicle A; Clamp A
Gynecol Oncol; 2023 May; 172():121-129. PubMed ID: 37030280
[TBL] [Abstract][Full Text] [Related]
2. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
[TBL] [Abstract][Full Text] [Related]
3. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Poveda A; Lheureux S; Colombo N; Cibula D; Lindemann K; Weberpals J; Bjurberg M; Oaknin A; Sikorska M; González-Martín A; Madry R; Pérez MJR; Ledermann J; Davidson R; Blakeley C; Bennett J; Barnicle A; Škof E
Gynecol Oncol; 2022 Mar; 164(3):498-504. PubMed ID: 35063276
[TBL] [Abstract][Full Text] [Related]
4. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
[TBL] [Abstract][Full Text] [Related]
5. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
[TBL] [Abstract][Full Text] [Related]
6. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Pujade-Lauraine E; Selle F; Scambia G; Asselain B; Marmé F; Lindemann K; Colombo N; Mądry R; Glasspool R; Vergote I; Korach J; Lheureux S; Dubot C; Oaknin A; Zamagni C; Heitz F; Gladieff L; Rubio-Pérez MJ; Scollo P; Blakeley C; Shaw B; Ray-Coquard I; Redondo A;
Ann Oncol; 2023 Dec; 34(12):1152-1164. PubMed ID: 37797734
[TBL] [Abstract][Full Text] [Related]
7. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
8. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
9. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract][Full Text] [Related]
10. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel BJ; Buss MK; Nattam SR; Hurteau J; Luo W; Curtis J; Whalen C; Kohn EC; Ivy SP; Matulonis UA
Ann Oncol; 2019 Apr; 30(4):551-557. PubMed ID: 30753272
[TBL] [Abstract][Full Text] [Related]
11. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
12.
Mirza MR; Lindahl G; Mahner S; Redondo A; Fabbro M; Rimel BJ; Herrstedt J; Oza AM; Canzler U; Berek JS; González-Martín A; Follana P; Lord R; Azodi M; Estenson K; Wang Z; Li Y; Gupta D; Matulonis U; Feng B
Cancer Res Commun; 2022 Nov; 2(11):1436-1444. PubMed ID: 36970052
[TBL] [Abstract][Full Text] [Related]
13. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
14. Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.
Liu J; Yin R; Wu L; Zhu J; Lou G; Wu X; Zhou Q; Gao Y; Kong B; Lu X; Wang J; Chen Y; Cheng Y; Wang Y; Lu W; Li W; Ma X; Hsu K
Asia Pac J Clin Oncol; 2022 Dec; 18(6):714-722. PubMed ID: 35357078
[TBL] [Abstract][Full Text] [Related]
15. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.
Morgan RD; Clamp AR; White DJ; Price M; Burghel GJ; Ryder WDJ; Mahmood RD; Murphy AD; Hasan J; Mitchell CL; Salih Z; Wheeler C; Buckley E; Truelove J; King G; Ainaoui Y; Bhaskar SS; Shaw J; Evans DGR; Kilerci B; Pearce SP; Brady G; Dive C; O'Connor JPB; Wallace AJ; Rothwell DG; Edmondson RJ; Jayson GC
Clin Cancer Res; 2023 Jul; 29(14):2602-2611. PubMed ID: 36799931
[TBL] [Abstract][Full Text] [Related]
16. Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
Gao Q; Zhu J; Zhao W; Huang Y; An R; Zheng H; Qu P; Wang L; Zhou Q; Wang D; Lou G; Wang J; Wang K; Low J; Kong B; Rozita AM; Sen LC; Yin R; Xie X; Liu J; Sun W; Su J; Zhang C; Zang R; Ma D
Clin Cancer Res; 2022 Jun; 28(11):2278-2285. PubMed ID: 35131903
[TBL] [Abstract][Full Text] [Related]
17. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT; Valencia RV; Cibula D; Colombo N; Leath CA; Bidziński M; Kim JW; Nam JH; Madry R; Hernández C; Mora PAR; Ryu SY; Milenkova T; Lowe ES; Barker L; Scambia G
J Clin Oncol; 2020 Apr; 38(11):1164-1174. PubMed ID: 32073956
[TBL] [Abstract][Full Text] [Related]
18. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
[TBL] [Abstract][Full Text] [Related]
19. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract][Full Text] [Related]
20. Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
Bourien H; Lefevre LB; Mouret-Reynier MA; Asselain B; Lucas B; Gavoille C; Cornila C; Gavoille L; Colomba E; Patsouris A; Fabbro M; Chakiba C; Toussaint P; Simon H; Berton D; Garbay D; Tixidre CG; Coeffic D; Morvan A; Collard O; DE LA Motte Rouge T
Anticancer Res; 2023 Feb; 43(2):653-662. PubMed ID: 36697069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
